Abstract: A simple and efficient method for the production of stable, clear, high-potency oat extracts is disclosed. The method employs the use of differential dissociation constants and ultrafiltration to stabilise extracts, prevent hazing, and prevent the loss of functional activity as an anti-irritant and anti-oxidant. Also disclosed are compositions of oat extracts derived from whole oat grains and oatmeal. Further disclosed are compositions of oat extracts for use in cosmetic, nutraceutical, therapeutic medical and veterinary preparations.

Abstract: A simple and efficient method for the production of stable, clear, high-potency oat extracts is disclosed. The method employs the use of differential dissociation constants and ultrafiltration to stabilise extracts, prevent hazing, and prevent the loss of functional activity as an anti-irritant and anti-oxidant. Also disclosed are compositions of oat extracts derived from whole oat grains and oatmeal. Further disclosed are compositions of oat extracts for use in cosmetic, nutraceutical, therapeutic medical and veterinary preparations.

Abstract: Cereal ?(1-3) ?(1-4) glucan is used as a film or coating agent to produce clear, edible, biodegradable, delivery, lubricating, and protecting agents. Cereal ?(1-3) ?(1-4) glucans are distinctive polymers of glucose differentiated from other polymers by not only their source but also their physicochemical properties. The ?(1-3) ?(1-4) forms a matrix to sequester other materials, such as pharmaceutical, medical and therapeutic agents, flavors, fragrances. The technology has applications to essential oils and non-aqueous materials that are rendered deliverable by the ?(1-3) ?(1-4) glucan. The ?(1-3) ?(1-4) glucan films described may be consumed whereby they dissolve in the mouth in a controlled manner and may be used for the delivery of pharmaceutical, medical or confectionery products.

Abstract: A simple and efficient method for the production of stable, clear, high-potency oat extracts is disclosed. The method employs the use of differential dissociation constants and ultrafiltration to stabilize extracts, prevent hazing, and prevent the loss of functional activity as an anti-irritant and anti-oxidant. Also disclosed are compositions of oat extracts derived from whole oat grains and oatmeal. Further disclosed are compositions of oat extracts for use in cosmetic, nutraceutical, therapeutic medical and veterinary preparations.

Abstract: A simple and efficient method for the production of stable, clear, high-potency oat extracts is disclosed. The method employs the use of differential dissociation constants and ultrafiltration to stabilise extracts, prevent hazing, and prevent the loss of functional activity as an anti-irritant and anti-oxidant. Also disclosed are compositions of oat extracts derived from whole oat grains and oatmeal. Further disclosed are compositions of oat extracts for use in cosmetic, nutraceutical, therapeutic medical and veterinary preparations.

Abstract: The present invention relates to oral compositions comprising a ? (1-3) ? (1-4) glucan and one, or more than one compound of interest. In particular, the present invention provides an oral composition comprising an effective amount of a ? (1-3) ? (1-4) glucan and an effective amount of one, or more than one of an antibacterial agent, a botanical extract, and a flavouring agent, and also provides a method of using this composition for maintaining fresh breath in a subject over a prolonged period of time.

Abstract: A simple and efficient method for the production of stable, clear, high-potency oat extracts is disclosed. The method employs the use of differential dissociation constants and ultrafiltration to stabilize extracts, prevent hazing, and prevent the loss of functional activity as an anti-irritant and anti-oxidant. Also disclosed are compositions of oat extracts derived from whole oat grains and oatmeal. Further disclosed are compositions of oat extracts for use in cosmetic, nutraceutical, therapeutic medical and veterinary preparations.

Abstract: The present invention relates to pharmaceutical compositions comprising a ? (1-3) ? (1-4) glucan and a pharmaceutically active agent or a botanical extract. A method to extract and purify cereal ?-glucan is also described. The high purity of the cereal ?-glucan obtained according to the present invention allows for the preparation of clear, colourless viscous liquid preparations. These liquid preparations are stable to gelling effects when kept at ambient temperatures and low ash concentrations, and can be used to prepare the pharmaceutical compositions of the present invention.

Abstract: Methods and compositions for treating or preventing a skin condition, an inflammation, an irritation or an allergy associated with an ectoparasitic infection or infestation on an animal.

Abstract: Cereal ?(1-3) ?(1-4) glucan is used as a film or coating agent to produce clear, edible, biodegradable, delivery, lubricating, and protecting agents. Cereal ?(1-3) ?(1-4) glucans are distinctive polymers of glucose differentiated from other polymers by not only their source but also their physicochemical properties. The ?(1-3) ?(1-4) forms a matrix to sequester other materials, such as pharmaceutical, medical and therapeutic agents, flavours, fragrances. The technology has applications to essential oils and non-aqueous materials that are rendered deliverable by the ?(1-3) ?(1-4) glucan. The ?(1-3) ?(1-4) glucan films described may be consumed whereby they dissolve in the mouth in a controlled manner and may be used for the delivery of pharmaceutical, medical or confectionery products.

Abstract: A simple and efficient method for the production of a stable, clear and high-potency oat extract, containing avenanthramide, is disclosed. The method employs the use of a differential dissociation constants and ultra filtration to stabilize extract, prevent the loss of functional activity as an anti-irritant and anti-oxidant.

Abstract: New immunological carrier systems, DNA encoding the same, and the use of these systems, are disclosed. The carrier systems include chimeric proteins which comprise a leukotoxin polypeptide fused to a selected antigen. The leukotoxin functions to increase the immunogenicity of the antigen fused thereto.

Abstract: A process is described for the isolation, recovery and purification of non-polar extractives using one or more extracting solvents from the group of lower alcohols, ketones, and water. The non-polar extractives may include one or more of the classes alk(en)lyresorcinols, steroid, triterpenoid and cardiac glycosides and saponins, steryl ferulates and other phenolic acid conjugates, flavoroids, polar lipids, alcohol-soluble antimicrobials, prolamines and other alcohol-soluble proteolipids complexes. The process uses an aliphatic-substituted polysaccharide gel matrix in a process of hydrophobic interaction chromatography, and involves the steps of absorption, washing and recovery, wherein the extractives are absorbed and desorbed in the presence of and as a result of the concentration and selection of the organic ste of regenerating the gel matrix for further use.

Abstract: Simple and efficient methods for formulating cereal beta glucan compositions that retard the natural gel forming properties of hydrocolloids and remain free flowing liquids is disclosed. The method employs a biological buffer system consisting of a zwitterionic salt that will vary pH with temperature. The resulting beta glucan preparation can be used directly or stored for future use.

Abstract: A number of subunits of various rotaviral proteins have been shown to be useful in diagnosis, therapy, and prevention of rotaviral infection. Specifically, the subunits represented by positions 40-60 of VP6, 232-255 and 240-248 of VP4, and 247-259 and 275-295 of VP7 are thus useful. Furthermore, the VP4 subunits have therapeutic value in competing with the native viral protein in an essential step in infection.

Abstract: Adjuvant formulations are provided containing quaternary ammonium salts in conjunction with an oil component which may be a mineral oil, an animal oil, a vegetable oil, a mixture thereof, or an oil-in-water emulsion of one or more of such oils. These formulations are useful in conjunction with known immunological substances, e.g., viral or bacterial antigens in a vaccine composition, in order to enhance the immunogenic response. The compositions are also useful without an incorporated antigen as nonspecific immunostimulatory formulations.

Abstract: New immunological carrier systems, DNA encoding the same, and the use of these systems, are disclosed. The carrier systems include chimeric proteins which comprise a leukotoxin polypeptide fused to a selected antigen. The leukotoxin functions to increase the immunogenicity of the antigen fused thereto.

Abstract: Novel Quinoa saponin pharmaceutical compositions are disclosed. The compositions are useful for enhancing mucosal absorption of a drug administered therewith.

Abstract: Novel Quinoa saponin pharmaceutical compositions are disclosed. The compositions are useful as immunological adjuvants, to stimulate nonspecific immunity, as well as to enhance an immunological response to a selected antigen. The Quinoa saponin compositions can also be used to enhance mucosal absorption of a drug administered therewith.

Abstract: Compositions and methods for preparing and delivering encapsulated biologically active agents to specific cell types are disclosed. Substances can be encapsulated in the VP6 inner capsid protein of rotavirus and delivered to selected cells, tissues and organs. Targeting agents can be linked to the surface of the VP6 sphere so that appropriate agents can be delivered to preselected cells and tissue types.